Lymerix is off the market

April 2002

The Lyme vaccine Lymerix is off the market due to poor sales.

Many factors may have contributed to the low demand. Lymerix is expensive...used in just a few states...and isn't very effective.

It has also gotten a lot of bad press.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new guidelines for PREVENTING type 2 diabetes
Cardiology ACE inhibitors and angiotensin receptor blockers are especially beneficial for preventing stroke
Cardiology More patients will be taking Plavix (clopidogrel)
Cardiology continuing statins when patients are hospitalized for severe chest pain
Osteoporosis latest thinking on treating osteoporosis in postmenopausal women
Vaccines current vaccine shortages
Vaccines Lymerix is off the market
Alzheimer's Disease link between homocysteine and dementia
Diabetes metformin can lower vitamin B12 levels
Diabetes stronger warnings about Actos and heart failure
Diabetes confused about the "sugar-free" candies marketed to patients with diabetes
Obesity & Weight Loss new concerns about the safety of Meridia (sibutramine)
Obesity & Weight Loss natural weight loss products
nocebo effect
Practice Claritin will soon go OTC